 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 February 1995 | Volume 122 Issue 3 | Pages 161-168
Objective: To analyze the distribution of hepatitis C virus (HCV) genotypes among patients positive for antibody to HCV (anti-HCV) according to age, severity of liver disease, and duration of infection; to investigate the influence of HCV genotypes on response to interferon-
Design: Cross-sectional study.
Setting: 3 university hospitals and 2 research units.
Patients: 3 groups of French and Italian patients with chronic HCV infection and detectable serum HCV RNA: Group 1 included 35 patients with hepatocellular carcinoma; group 2, 71 patients with cirrhosis who did not have hepatocellular carcinoma; and group 3, 114 patients with chronic active hepatitis. 106 of the patients with chronic hepatitis or cirrhosis were treated with interferon-
Measurements: Genotyping by polymerase chain reaction with capsid-specific primers; serum HCV RNA by branched DNA (bDNA) signal amplification.
Results: Hepatitis C virus genotype 1b (II) was the most prevalent genotype (61.8%). In a univariate analysis, it was associated with older age (<40 years, 47.4%;
Conclusions: The prevalence of HCV genotypes in French and Italian patients has been changing; the prevalence of HCV type 1b (II) infection has progressively decreased, although it still accounts for most HCV-related cirrhosis and hepatocellular carcinoma. High HCV viremia levels and HCV genotype type 1b (II) are independent predictors for poor response to interferon-
For affiliations and current author addresses, see end of text.
*For a listing of collaborators, see Appendix 2.
Author and Article Information
From Hopital Necker, Institut Pasteur, and Hopital P. Brousse, Paris, France; Jichi Medical School, Tochigi-Ken, Japan; and University of Milan, Milan, Italy.
ARTICLE
Hepatitis C Virus Type 1b (II) Infection in France and Italy
therapy; and to study HCV viremia levels in relation to genotypes and severity of liver disease. (3 MU subcutaneously 3 times/wk for 
6 months). 60 years, 80.4%; P = 0.001), longer duration of disease (
10 years, 40.4%; 20 years, 86.7%; P = 0.005), and cirrhosis with or without hepatocellular carcinoma (78.4% compared with 53.8% for chronic hepatitis; P < 0.001). Viremia levels did not differ between patients infected with HCV type 1b (II) and those infected with other HCV genotypes. Patients with HCV type 1b (II) responded to interferon- therapy significantly less than did patients with other HCV genotypes (P = 0.01). In a multivariate analysis, age and cirrhosis were independently associated with HCV genotype 1b (II). Genotype and HCV viremia level were independent predictors of response to interferon- therapy. therapy and should be considered in the management of patients with HCV infection.
Request for Reprints: Christian Brechot, MD, PhD, Inserm U 370, CHU Necker, 156, rue de Vaugirard, 75015 Paris, France.
For a listing of collaborators, see Appendix 2.
Grant Support: In part by Institut National de la Sante et de la Recherche Medicale, Pasteur Institute, Diagnostic Pasteur Sanofi, European Community, Association pour la Recherche contre le Cancer, Caisse Nationale d'Assurance Maladie and Fondation pour la Recherche Medicale (JN).
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  M. Abdel-Hamid, M. El-Daly, V. Molnegren, S. El-Kafrawy, S. Abdel-Latif, G. Esmat, G. T. Strickland, C. Loffredo, J. Albert, and A. Widell Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma J. Gen. Virol., May 1, 2007; 88(5): 1526 - 1531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Bortolotti, M Resti, M Marcellini, R Giacchino, G Verucchi, G Nebbia, L Zancan, M G Marazzi, C Barbera, A Maccabruni, et al. Hepatitis C virus (HCV) genotypes in 373 Italian children with HCV infection: changing distribution and correlation with clinical features and outcome Gut, June 1, 2005; 54(6): 852 - 857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M G Rumi, F De Filippi, C La Vecchia, M F Donato, S Gallus, E Del Ninno, and M Colombo Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients Gut, March 1, 2005; 54(3): 402 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Taguchi, M. Nagano-Fujii, M. Akutsu, H. Kadoya, S. Ohgimoto, S. Ishido, and H. Hotta Hepatitis C virus NS5A protein interacts with 2',5'-oligoadenylate synthetase and inhibits antiviral activity of IFN in an IFN sensitivity-determining region-independent manner J. Gen. Virol., April 1, 2004; 85(4): 959 - 969. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. K. Henderson Managing Occupational Risks for Hepatitis C Transmission in the Health Care Setting Clin. Microbiol. Rev., July 1, 2003; 16(3): 546 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ogata, R. Huab Florese, M. Nagano-Fujii, R. Hidajat, L. Deng, Y. Ku, S. Yoon, T. Saito, S. Kawata, and H. Hotta Identification of Hepatitis C Virus (HCV) Subtype 1b Strains That Are Highly, or Only Weakly, Associated with Hepatocellular Carcinoma on the Basis of the Secondary Structure of an Amino-Terminal Portion of the HCV NS3 Protein J. Clin. Microbiol., July 1, 2003; 41(7): 2835 - 2841. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-A. Sun, D.-M. Wu, C.-C. Lin, S.-N. Lu, S.-L. You, L.-Y. Wang, M.-H. Wu, and C.-J. Chen Incidence and Cofactors of Hepatitis C Virus-related Hepatocellular Carcinoma: A Prospective Study of 12,008 Men in Taiwan Am. J. Epidemiol., April 15, 2003; 157(8): 674 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ogata, M. Nagano-Fujii, Y. Ku, S. Yoon, and H. Hotta Comparative Sequence Analysis of the Core Protein and Its Frameshift Product, the F Protein, of Hepatitis C Virus Subtype 1b Strains Obtained from Patients with and without Hepatocellular Carcinoma J. Clin. Microbiol., October 1, 2002; 40(10): 3625 - 3630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Chen and K. E. Weck Hepatitis C Virus Genotyping: Interrogation of the 5' Untranslated Region Cannot Accurately Distinguish Genotypes 1a and 1b J. Clin. Microbiol., September 1, 2002; 40(9): 3127 - 3134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gigou, A. M. Roque-Afonso, B. Falissard, F. Penin, E. Dussaix, and C. Feray Genetic Clustering of Hepatitis C Virus Strains and Severity of Recurrent Hepatitis after Liver Transplantation J. Virol., December 1, 2001; 75(23): 11292 - 11297. [Abstract] [Full Text]
|
|
|
|
|
|
I Nakano, Y Fukuda, Y Katano, H Toyoda, K Hayashi, T Hayakawa, T Kumada, and S Nakano Interferon responsiveness in patients infected with hepatitis C virus 1b differs depending on viral subtype Gut, August 1, 2001; 49(2): 263 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S D Taylor-Robinson, M B Toledano, S Arora, T J Keegan, S Hargreaves, A Beck, S A Khan, P Elliott, and H C Thomas Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998 Gut, June 1, 2001; 48(6): 816 - 820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Morice, D. Roulot, V. Grando, J. Stirnemann, E. Gault, V. Jeantils, M. Bentata, B. Jarrousse, O. Lortholary, C. Pallier, et al. Phylogenetic analyses confirm the high prevalence of hepatitis C virus (HCV) type 4 in the Seine-Saint-Denis district (France) and indicate seven different HCV-4 subtypes linked to two different epidemiological patterns J. Gen. Virol., May 1, 2001; 82(5): 1001 - 1012. [Abstract] [Full Text]
|
|
|
|
|
|
T. Laskus, L.-F. Wang, M. Radkowski, H. Vargas, M. Nowicki, J. Wilkinson, and J. Rakela Exposure of Hepatitis C Virus (HCV) RNA-Positive Recipients to HCV RNA-Positive Blood Donors Results in Rapid Predominance of a Single Donor Strain and Exclusion and/or Suppression of the Recipient Strain J. Virol., March 1, 2001; 75(5): 2059 - 2066. [Abstract] [Full Text]
|
|
|
|
|
|
J.-B. Nousbaum, S. J. Polyak, S. C. Ray, D. G. Sullivan, A. M. Larson, R. L. Carithers Jr., and D. R. Gretch Prospective Characterization of Full-Length Hepatitis C Virus NS5A Quasispecies during Induction and Combination Antiviral Therapy J. Virol., October 1, 2000; 74(19): 9028 - 9038. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. Zylberberg, M. L. Chaix, and C. Brechot Infection with Hepatitis C Virus Genotype 4 Is Associated with a Poor Response to Interferon-{alpha} Ann Intern Med, May 16, 2000; 132(10): 845 - 846. [Full Text] [PDF]
|
|
|
|
 |
|
 D. K. Strickland, C. A. Riely, C. C. Patrick, D. Jones-Wallace, J. M. Boyett, B. Waters, J. F. Fleckenstein, P. J. Dean, R. Davila, T. E. Caver, et al. Hepatitis C infection among survivors of childhood cancer Blood, May 15, 2000; 95(10): 3065 - 3070. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. N. Zein Clinical Significance of Hepatitis C Virus Genotypes Clin. Microbiol. Rev., April 1, 2000; 13(2): 223 - 235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Cabot, M. Martell, J. I. Esteban, S. Sauleda, T. Otero, R. Esteban, J. Guàrdia, and J. Gómez Nucleotide and Amino Acid Complexity of Hepatitis C Virus Quasispecies in Serum and Liver J. Virol., January 1, 2000; 74(2): 805 - 811. [Abstract] [Full Text]
|
|
|
|
 |
|
 A.-R. N. ZEKRI, A. A. BAHNASSY, S. M. SHAARAWY, O. A. MANSOUR, M. A. MADUAR, H. M. KHALED, and O. EL-AHMADI Hepatitis C virus genotyping in relation to neu-oncoprotein overexpression and the development of hepatocellular carcinoma J. Med. Microbiol., January 1, 2000; 49(1): 89 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D Taylor-Robinson, H. C Thomas, S. Arora, and S. Hargreaves Increased mortality from liver cancer in England and Wales is not related to hepatitis C BMJ, September 4, 1999; 319(7210): 640 - 640. [Full Text]
|
|
|
|
|
|
H. Yoshida, Y. Shiratori, M. Moriyama, Y. Arakawa, T. Ide, M. Sata, O. Inoue, M. Yano, M. Tanaka, S. Fujiyama, et al. Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan Ann Intern Med, August 3, 1999; 131(3): 174 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Honda, R. Rijnbrand, G. Abell, D. Kim, and S. M. Lemon Natural Variation in Translational Activities of the 5' Nontranslated RNAs of Hepatitis C Virus Genotypes 1a and 1b: Evidence for a Long-Range RNA-RNA Interaction outside of the Internal Ribosomal Entry Site J. Virol., June 1, 1999; 73(6): 4941 - 4951. [Abstract] [Full Text]
|
|
|
|
|
|
S Bellentani, G Pozzato, G Saccoccio, M Crovatto, L S Croce, L Mazzoran, F Masutti, G Cristianini, and C Tiribelli Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study Gut, June 1, 1999; 44(6): 874 - 880. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Wong, W. G. Bennett, R. S. Koff, and S. G. Pauker Pretreatment Evaluation of Chronic Hepatitis C: Risks, Benefits, and Costs JAMA, December 23, 1998; 280(24): 2088 - 2093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Resti, C. Azzari, F. Mannelli, M. Moriondo, E. Novembre, M. de Martino, A. Vierucci, Tuscany Study Group on Hepatitis C Virus Infection, M. Resti, C. Azzari, et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1 • Science commentary: Behaviour of hepatitis C virus BMJ, August 15, 1998; 317(7156): 437 - 441. [Abstract] [Full Text]
|
|
|
|
|
|
L De Moliner, P Pontisso, G L De Salvo, L Cavalletto, L Chemello, and A Alberti Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features Gut, June 1, 1998; 42(6): 856 - 860. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-M. Pawlotsky, G. Germanidis, A. U. Neumann, M. Pellerin, P.-O. Frainais, and D. Dhumeaux Interferon Resistance of Hepatitis C Virus Genotype 1b: Relationship to Nonstructural 5A Gene Quasispecies Mutations J. Virol., April 1, 1998; 72(4): 2795 - 2805. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Locasciulli, M. Testa, P. Pontisso, L. Benvegnu, D. Fraschini, A. Corbetta, F. Noventa, G. Masera, and A. Alberti Prevalence and Natural History of Hepatitis C Infection in Patients Cured of Childhood Leukemia Blood, December 1, 1997; 90(11): 4628 - 4633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Rumi, E. Santagostino, M. Morfini, A. Gringeri, G. Tagariello, A. Chistolini, P. Pontisso, A. Tagger, M. Colombo, P.M. Mannucci, et al. A Multicenter Controlled, Randomized, Open Trial of Interferon alpha 2b Treatment of Anti-Human Immunodeficiency Virus-Negative Hemophilic Patients With Chronic Hepatitis C Blood, May 15, 1997; 89(10): 3529 - 3533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Hoofnagle and A. M. Di Bisceglie The Treatment of Chronic Viral Hepatitis N. Engl. J. Med., January 30, 1997; 336(5): 347 - 356. [Full Text] [PDF]
|
|
|
|
|
|
N. Enomoto, I. Sakuma, Y. Asahina, M. Kurosaki, T. Murakami, C. Yamamoto, Y. Ogura, N. Izumi, F. Marumo, and C. Sato Mutations in the Nonstructural Protein 5a Gene and Response to Interferon in Patients with Chronic Hepatitis C Virus 1b Infection N. Engl. J. Med., January 11, 1996; 334(2): 77 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Levin and C. Amos Therapy of Unresectable Hepatocellular Carcinoma N. Engl. J. Med., May 11, 1995; 332(19): 1294 - 1296. [Full Text]
|
|
Article
